Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

13.79 +0.22 (+1.66%)

Streaming Delayed Price Updated: 10:56 AM EST, Dec 8, 2025 Add to My Watchlist

Price and Volume

Volume	93,761
Open	13.80
Bid (Size)	13.66 (100)
Ask (Size)	13.92 (300)
Prev. Close	13.56
Today's Range	13.60 - 14.29
52wk Range	4.880 - 19.58
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Let's take a look at the stocks that are in motion in today's session. ↗

December 03, 2025

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

Via Chartmill

These stocks are moving in today's session ↗

December 03, 2025

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Performance

YTD	-3.7%	-3.7%
1 Month	+35.9%	+35.9%
3 Month	+68.1%	+68.1%
6 Month	+18.0%	+18.0%
1 Year	-3.7%	-3.7%

More News

Which stocks are gapping on Wednesday? ↗

December 03, 2025

Via Chartmill

Which stocks are moving after the closing bell on Tuesday? ↗

December 02, 2025

Via Chartmill

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

November 25, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

November 13, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

November 11, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗

November 07, 2025

Via Benzinga

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

November 04, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

November 03, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

November 03, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

October 22, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

October 08, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

This Coinbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

October 01, 2025

Via Benzinga

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

September 23, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

September 04, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

August 27, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 13, 2025

Via Benzinga

Aardvark Therapeutics Reports Q2 Loss ↗

August 13, 2025

Via The Motley Fool

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

August 13, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

August 12, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

July 18, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress ↗

June 30, 2025

Via Benzinga

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

June 24, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

May 19, 2025

From Aardvark Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Aardvark Therapeutics, Inc. - Common Stock publicly traded?

Yes, Aardvark Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Aardvark Therapeutics, Inc. - Common Stock trade on?

Aardvark Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Aardvark Therapeutics, Inc. - Common Stock?

The ticker symbol for Aardvark Therapeutics, Inc. - Common Stock is AARD on the Nasdaq Stock Market

What is the current price of Aardvark Therapeutics, Inc. - Common Stock?

The current price of Aardvark Therapeutics, Inc. - Common Stock is 13.79

When was Aardvark Therapeutics, Inc. - Common Stock last traded?

The last trade of Aardvark Therapeutics, Inc. - Common Stock was at 12/08/25 10:56 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.